Serum Alkaline Phosphatase Predicts Survival Outcomes in Patients with Skeletal Metastatic Nasopharyngeal Carcinoma

Overview

Journal Clinics (Sao Paulo)

Publisher Elsevier

Specialty General Medicine

Date 2015 May 29

PMID 26017793

Citations 20

Authors

Ying Jin

Mei-Qin Yuan

Jun-Qing Chen

Yi-Ping Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: Bone metastasis is frequently associated with nasopharyngeal carcinoma. The diagnosis and follow-up of bone metastatic patients usually relies on skeletal X-ray and bone scintigraphy, which are time-consuming and costly. This study aimed to evaluate whether serum alkaline phosphatase offers clinical value in predicting the clinical response and survival outcome for skeletal metastatic nasopharyngeal carcinoma.

Methods: Serum alkaline phosphatase was measured at baseline and then before each cycle of treatment in 416 nasopharyngeal carcinoma patients with bone metastasis. The correlations between the pre-treatment and post-treatment alkaline phosphatase levels and the treatment efficacy were analyzed using the chi-square test. Survival was analyzed using the Kaplan-Meier method and then compared using the log-rank test.

Results: Patients with elevated pre-treatment alkaline phosphatase (>110 IU/L) had significantly worse progression-free survival (P<0.001) and overall survival (P<0.001) than those with a normal level of this marker (≤110 IU/L). Patients with elevated post-treatment alkaline phosphatase had worse progression-free survival (P<0.001) and overall survival (P<0.001) compared with those with a normal level. Patients with normal pre-treatment and post-treatment alkaline phosphatase showed the most favorable prognosis. The Cox multivariate analysis revealed that only the pre-treatment and post-treatment alkaline phosphatase levels were independent prognostic factors for progression-free survival (HR ϝ 1.656, P<0.001; HR ϝ 2.226, P<0.001) and for overall survival (HR ϝ 1.794, P<0.001; HR ϝ 2.657, P<0.001).

Conclusions: Serum alkaline phosphatase appears to be a significant independent prognostic index in patients with skeletal metastatic nasopharyngeal carcinoma, which could reflect the short-term treatment response of palliative chemotherapy and the long-term survival outcomes.

Citing Articles

Association between alkaline phosphatase levels and mortality in Chinese patients with colorectal cancer with liver metastases: a retrospective cohort study.

Liu Z, Zhang Z, Yu G, Mo M, Xie C, Xu D Therap Adv Gastroenterol. 2025; 18():17562848241311114.

PMID: 39846079 PMC: 11752734. DOI: 10.1177/17562848241311114.

Integrated noninvasive diagnostics for prediction of survival in immunotherapy.

Yeghaian M, Bodalal Z, Tareco Bucho T, Kurilova I, Blank C, Smit E Immunooncol Technol. 2024; 24:100723.

PMID: 39185322 PMC: 11342748. DOI: 10.1016/j.iotech.2024.100723.

Correlation between initial alkaline phosphatase levels and overall survival in newly diagnosed multiple myeloma patients.

Tan J, Liu J, Yao X, Xu Z, Wu Y, Shi X Transl Cancer Res. 2024; 13(7):3328-3337.

PMID: 39145085 PMC: 11319959. DOI: 10.21037/tcr-24-330.

FDG PET/CT reveals bone marrow oligometastasis in laryngeal squamous carcinoma: a case report with favorable outcome.

Al-Ibraheem A, Al-Adhami D, Abdlkadir A, Mohamad I, Ghatasheh H, Qandeel M BJR Case Rep. 2023; 9(6):20230065.

PMID: 37928713 PMC: 10621579. DOI: 10.1259/bjrcr.20230065.

Development and validation of prognostic nomograms based on De Ritis ratio and clinicopathological features for patients with stage II/III colorectal cancer.

Fu J, Du F, Tian T, Huang H, Zhang L, Li D BMC Cancer. 2023; 23(1):620.

PMID: 37400788 PMC: 10318767. DOI: 10.1186/s12885-023-11125-5.

References

Ogose A, Hotta T, Kawashima H, Hatano H, Umezu H, Inoue Y . Elevation of serum alkaline phosphatase in clear cell chondrosarcoma of bone. Anticancer Res. 2001; 21(1B):649-55. View

Chiesa F, De Paoli F . Distant metastases from nasopharyngeal cancer. ORL J Otorhinolaryngol Relat Spec. 2001; 63(4):214-6. DOI: 10.1159/000055743. View

Mundy G . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2(8):584-93. DOI: 10.1038/nrc867. View

Yu M, Yuan J . Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol. 2002; 12(6):421-9. DOI: 10.1016/s1044579x02000858. View

Kanakis I, Nikolaou M, Pectasides D, Kiamouris C, Karamanos N . Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal. 2004; 34(4):827-32. DOI: 10.1016/S0731-7085(03)00567-3. View

Roodman G . Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-64. DOI: 10.1056/NEJMra030831. View

BERGMEYER H, BOWERS Jr G, Horder M, Moss D . Provisional recommendations on IFCC methods for the measurement of catalytic concentrations of enzymes. Part 2. IFCC method for aspartate aminotransferase. Clin Chim Acta. 1976; 70(2):F19-29. View

Lu Y, Lu Q, Chen H . Diagnosis of primary liver cancer using lectin affinity chromatography of serum alkaline phosphatase. J Exp Clin Cancer Res. 1997; 16(1):75-80. View

Li X, Mortensen B, Rushfeldt C, Huseby N . Serum gamma-glutamyltransferase and alkaline phosphatase during experimental liver metastases. Detection of tumour-specific isoforms and factors affecting their serum levels. Eur J Cancer. 1999; 34(12):1935-40. DOI: 10.1016/s0959-8049(98)00196-8. View

10.

Chang E, Adami H . The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1765-77. DOI: 10.1158/1055-9965.EPI-06-0353. View

11.

Guise T, Mohammad K, Clines G, Stebbins E, Wong D, Higgins L . Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006; 12(20 Pt 2):6213s-6216s. DOI: 10.1158/1078-0432.CCR-06-1007. View

12.

Bashiri A, Katz O, Maor E, Sheiner E, Pack I, Mazor M . Positive placental staining for alkaline phosphatase corresponding with extreme elevation of serum alkaline phosphatase during pregnancy. Arch Gynecol Obstet. 2006; 275(3):211-4. DOI: 10.1007/s00404-006-0212-5. View

13.

Kam M, Leung S, Zee B, Chau R, Suen J, Mo F . Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007; 25(31):4873-9. DOI: 10.1200/JCO.2007.11.5501. View

14.

Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S . The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res. 2007; 26(3):307-12. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Damera S, Raphael K, Baird B, Cheung A, Greene T, Beddhu S . Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Kidney Int. 2010; 79(2):228-33. PMC: 5260661. DOI: 10.1038/ki.2010.356. View

17.

Suva L, Washam C, Nicholas R, Griffin R . Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011; 7(4):208-18. PMC: 3134309. DOI: 10.1038/nrendo.2010.227. View

18.

Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H . Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2010; 128(2):79-85. DOI: 10.1016/j.anorl.2010.10.003. View

19.

Maisano R, Azzarello D, Del Medico P, Maisano M, Bottari M, Egitto G . Alkaline phosphatase levels as a prognostic factor in metastatic colorectal cancer treated with the FOLFOX 4 regimen: a monoinstitutional retrospective study. Tumori. 2011; 97(1):39-42. DOI: 10.1177/030089161109700108. View

20.

Jin Y, An X, Cai Y, Cao Y, Cai X, Xia Q . Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2011; 137(10):1545-51. DOI: 10.1007/s00432-011-1027-8. View